NEWS HIGHLIGHTSMedia Articles Related to Dovonex (Calcipotriene Topical)
International Psoriasis Council Hosts Second Educational Symposium To Increase Global Knowledge Of Psoriasis
Source: Dermatology News From Medical News Today [2009.11.18]
Beginning Thursday, Nov. 19, 2009, the International Psoriasis Council (IPC) will host its second symposium at Baylor University Medical Center in Dallas. The two-day conference brings together dermatologists from Asia, Eastern Europe and Spain to elevate the global understanding of psoriasis and its treatment. Sessions will be facilitated by leading dermatologists and nurses dedicated to psoriasis management and research.
Psoriatic arthritis common in people with psoriasis (Reuters)
Source: Y! Health Arthritis News [2009.11.05]
Reuters - As many as 14 percent of people with psoriasis may also have psoriatic arthritis, research shows.
EADV: Psoriasis Comorbidities May Cut Longevity (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- Psoriasis patients have a substantial comorbidity burden that can reduce life expectancy by 10 years or more, according to data presented here.
EADV: Benefit of Methrotrexate in Psoriasis Will Show Up Early (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- A suboptimal response to methotrexate at 12 weeks identified psoriasis patients who were unlikely to benefit from continued therapy at higher doses, a retrospective analysis of clinical-trial data showed.
EADV: Anti-TNF Exposure Does Not Rule out TNF Inhibitor for Psoriasis (CME/CE)
Source: MedPage Today Dermatology [2009.10.13]
BERLIN (MedPage Today) -- Prior exposure to anti-tumor necrosis factor (TNF) therapy does not rule out potential benefits from additional anti-TNF therapy for patients with psoriasis, according to data presented here.
Published Studies Related to Dovonex (Calcipotriene Topical)
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. [2009.01]
Topical corticosteroids are widely used in the treatment of psoriasis. This study was conducted to compare the efficacy and safety of clobetasol propionate (CP) 0.005% spray to calcipotriene 0.005%-betamethasome diproprionate 0.064% (C-BD) ointment in patients with moderate to severe plaque psoriasis...
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. [2008.09]
BACKGROUND: New topical treatments in scalp psoriasis are needed because many current topical treatments are disliked by patients and associated with poor compliance. OBJECTIVE: To compare the efficacy and safety of once-daily, two-compound scalp formulation containing calcipotriene plus betamethasone dipropionate with the individual components in the same vehicle and the vehicle alone... CONCLUSION: Calcipotriene plus betamethasone dipropionate scalp formulation was more effective than either of the individual components or the vehicle alone.
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. [2006.10]
BACKGROUND: The merit of topical sequential therapy involving clobetasol foam and calcipotriene ointment has not been experimentally demonstrated. OBJECTIVE: We sought to assess the short-term efficacy of twice-daily clobetasol foam plus calcipotriene ointment compared with either agent alone as monotherapy and to compare long-term use of weekday calcipotriene ointment with or without clobetasol foam weekend pulse therapy... CONCLUSION: The combination of clobetasol foam and calcipotriene ointment is significantly more effective than monotherapy for short-term treatment. Weekday calcipotriene plus weekend pulse clobetasol foam shows a consistent trend toward greater maintenance of remission.
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. [2003.01]
BACKGROUND: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. OBJECTIVE: We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone dipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone... CONCLUSION: A combination product of calcipotriene 50 microg/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris.
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. [2000.10]
BACKGROUND: Both tazarotene (a retinoid prodrug) and calcipotriene (a synthetic analog of vitamin D3) are effective in the treatment of plaque psoriasis, but no reports in the literature directly compare the efficacy and tolerability of these 2 drugs...
Clinical Trials Related to Dovonex (Calcipotriene Topical)
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris [Completed]
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with:
1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8
weeks of calcipotriol cream
2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks
of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate)
ointment on weekends
3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks
of vehicle of calcipotriol cream
The objective is to compare the efficacy and safety of the different treatment regimens
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis [Completed]
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of
calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment
of calcipotriol scalp solution in patients with scalp psoriasis. The primary outcome is
patients with clear or minimal disease after 8 weeks treatment.
Further the occurrence of relapse and rebound after end of treatment in patients with clear
or minimal disease will be investigated.
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis. [Recruiting]
This single arm study will evaluate the efficacy and safety of sequential treatment with
Diavobet (betamethasone propionate 0. 5mg/g plus calcipotriol hydrate 50 micrograms/g) once
daily for 4 weeks followed by Daivonex (calcipotriol hydrate 50 micrograms/g) twice daily for
4 weeks, in the control of signs and symptoms in patients with mild to moderate psoriasis.
Only patients showing a >50% response to Daivobet will progress to the Daivonex maintenance
phase. The anticipated time on study treatment is <3 months, and the target sample size is
100-500 individuals.
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis [Completed]
The purpose of the study is to evaluate whether once daily topical treatment for up to 8
weeks of calcipotriol 50 mcg/g plus betamethasone 0. 5 mg/g (as dipropionate) gel is safe and
more effective than betamethasone 0. 5 mg/g (as dipropionate) in the gel vehicle and
calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis.
The primary response criterion is the number of patients with absence of disease and very
mild disease after 8 weeks of treatment.
|
